Medicare covers a yearly appointment to discuss your plan of preventive care in the coming year. This appointment is called the Annual Wellness Visit. The Annual Wellness Visit is similar to the one-time Welcome to Medicare preventive visit but has important differences. For example, like the Welcome to Medicare visit, the Annual Wellness Visit is not a head-to-toe physical. However, you cannot receive your Annual Wellness Visit within the first year you are enrolled in Medicare or within the same year you have your Welcome to Medicare exam. During the first Annual Wellness Visit, your doctor or health care provider will create a prevention plan based on your needs.
We are pleased to announce the launch of our newly designed website! It is our hopes that the new site will provide a more user-friendly experience and serve you better. Take a few moments to navigate around and take a quick tour. As always, our goal is to make you feel at home and provide the best service and medical care possible.
CAHS is an industry leading multi-disciplinary Contract Research Organization (Medical Doctors of multiple specialties, PhDs, RDs, and PharmD) capable of designing and executing phase I-IV clinical trials within the dietary supplement, pharmaceutical, functional food and medical food industries.
Our diverse, innovative skill set and capabilities at CAHS allows us to delve deeper with both established and novel biomarkers into the underlying scientific mechanisms of an intervention. Furthermore, we seek to answer “real-world” questions on a product or intervention of interest by tying in the granular perspective of underlying mechanisms with an applied, global view using validated human clinical outcome measures or functional end points.
The U.S. Food and Drug Administration today approved Botox injection (onabotulinumtoxinA) to prevent headaches in adult patients with chronic migraine. Chronic migraine is defined as having a history of migraine and experiencing a headache on most days of the month.
“Chronic migraine is one of the most disabling forms of headache,” said Russell Katz, M.D., director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “Patients with chronic migraine experience a headache more than 14 days of the month. This condition can greatly affect family, work, and social life, so it is important to have a variety of effective treatment options available.”